Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is conducting a Phase 3 trial titled ‘A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).’ The study aims to compare the efficacy and safety of the BMS-986489 combination therapy against Atezolizumab, both paired with Carboplatin and Etoposide, in treating extensive-stage small cell lung cancer.
The intervention being tested is a combination of BMS-986489 (BMS-986012+Nivolumab), Carboplatin, and Etoposide, intended to serve as a first-line treatment option for extensive-stage small cell lung cancer. This combination is compared to Atezolizumab with Carboplatin and Etoposide.
The study is designed as a randomized, double-blind, multicenter trial with a parallel intervention model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on February 25, 2025, and the latest update was submitted on August 1, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results, which are yet to be submitted.
The outcome of this study could significantly impact Bristol-Myers Squibb’s stock performance and investor sentiment, as successful results may enhance the company’s competitive stance in the oncology market. This is particularly relevant given the competitive landscape with other pharmaceutical companies developing similar therapies.
The study is currently recruiting, with further details available on the ClinicalTrials portal.